Konstruktion und Charakterisierung Serotyp 5-basierter adenoviraler Vektoren zur Expression von Modellantigenen für genetische Vakzinierung
LizenzStandard (Fassung vom 01.10.2008)
Genetic immunization is a new approach in the development of vaccination strategies against infectious diseases. It involves the delivery of nucleic acids into target host cells for the expression of pathogen-derived antigens in situ to elicit a protective humoral and cell-mediated immune response. Several viral and non-viral gene transfer systems for the delivery of nucleic acids can be employed. Among these adenovirus vectors (Ad vectors) show great promise since they can infect a wide variety of dividing and non-dividing cells, do not integrate into the host cell genome and offer a high capacity for the genetic incorporation of transgenes. However, problems may arise due to pre-existing immunity and non-specific transduction of host cells. To address these problems a novel platform for so-called "genetichemical" capsid modification of Ad vectors has been developed that allows for modifying vector tropism and shielding. Objective of the work presented here was to construct non-modified and "genetichemically" modified Ad vectors which express the model antigens HBsAg and ovalbumin that can be used to study immune responses after genetic vaccination. The vectors were produced and characterized by genetic and biochemical techniques. Furthermore, vectors were injected into mice by different administration routes and immune responses to the expressed transgenes were evaluated.
Erstellung / Fertigstellung
Normierte SchlagwörterHepatitis-B-Surface-Antigen [GND]
Hepatitis B surface antigens [MeSH]